Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Personalized cell therapy LauT-1 enters human trials for advanced cancers

NCT ID NCT06889766

First seen May 20, 2026 · Last updated May 23, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called LauT-1 for people with advanced melanoma (a type of skin cancer) or sarcoma (a rare cancer of connective tissues). The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to see if the treatment is safe and possible to make. Only 9 participants will be enrolled in this single-center study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Hospitalier Universitaire Vaudois

    RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    NOT_YET_RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.